Argenx falls as Sjögren’s setback offsets celiac drug progress
Argenx shares dropped 15% after its Vyvgart drug failed a Phase 3 trial for Sjögren's disease. The company also reported positive Phase 2 results for a celiac disease drug, FB102. Analysts note the Sjögren's failure removes a potential $1.4B revenue opportunity, but Vyvgart's sales remain strong at $1.5B in Q2.
How this was made
The 30-second read
Why it matters
The negative trial result drives immediate share weakness, but the celiac data may provide a near‑term catalyst.
Market read
Primary biotech news with material impact on ARX stock price; limited broader market effect.
What to watch
Argenx's existing Vyvgart sales remain strong and the celiac Phase 2 data could offset some downside.
Background
Argenx announced a Phase 3 futility decision for its Sjögren's disease trial, while simultaneously reporting positive Phase 2 data for a celiac disease candidate.
Market effects
Biotech sector may see broader risk aversion toward FcRn inhibitor programs.
Limited to U.S. and European biotech investors.
Modest; primarily affects ARX and peers with similar pipelines.
Counterpoint
The setback may create a buying opportunity if the stock is oversold and the celiac program shows promise.
Key entities
- companyArgenx
Biotech firm developing Vyvgart and celiac candidate FB102.
